VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, has announced that it has obtained an American and European patent for TOTUM-070, its active substance dedicated to reducing LDL-cholesterol in the blood (“bad cholesterol”).
TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63). The patent has been granted for the United States, Europe and South Africa.
TOTUM-070 targets excess LDL-cholesterol, which is a well-known risk factor for cardiovascular disease and the main cause of atherosclerosis1. It is believed that over 174 million adults in the US and Europe will suffer from hypercholesterolemia in 2020. The market for non-prescription products is estimated at €1.2 billion in these regions2.
Sébastien Peltier, CEO of VALBIOTIS, said: “With TOTUM-070, we are targeting a major market, one in which we stand out for our specific plant know-how, a high level of clinical evidence and robust intellectual property worldwide. This strategy has already borne fruit, with a major partnership aiming at developping and marketing our first active substance, TOTUM-63. Obtaining this patent for TOTUM-070 in regions where populations are particularly affected by hypercholesterolemia marks a milestone in our development model aimed at building new partnerships of this scale.”
The TOTUM-070 patent covers a wide range of food and pharmaceutical applications relating to lipid metabolism disorders, for example dyslipidemia, cholesterol and triglycerides. It is the focus of an international filing strategy reaching beyond the United States and Europe.
A Phase II clinical study evaluating the efficacy of TOTUM-070 in people with untreated moderate hypercholesterolemia will be launched before the end of the year. The initiation of this study will be communicated subsequently.
The objective for VALBIOTIS is to obtain the first proprietary health claim for reducing LDL-cholesterol, notably in Europe and North America, for a product containing neither phytosterols nor red yeast rice.
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R20-018), these documents being available on the Company’s website (www.valbiotis.com).
1 2018 Guideline on the Management of Blood Cholesterol, a report from the American College of Cardiology / American Heart Association, Journal Of The American College Of Cardiology, 2019.
2 AEC Partners data for the United States and VALBIOTIS’ 5 priority European countries (Germany, Spain, France, Italy and the United Kingdom), 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005535/en/
Contact information
CORPORATE COMMUNICATION / VALBIOTIS
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
media@valbiotis.com
FINANCIAL COMMUNICATION / ACTIFIN
Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regula Contributes Industry Expertise to Two New Analyst Reports on Document Fraud and Identity Verification Trends6.1.2026 15:00:00 EET | Press release
Regula, a global developer of identity verification solutions and forensic devices, has contributed its expert knowledge to two new analyst reports by Forrester Research. With more than 30 years of experience in forensic document examination and decades of collaboration with border agencies worldwide, Regula contributed as a domain expert in document forensics and identity verification. Contribution to “The State of Document Fraud Management” This report, authored by Andras Cser, VP Principal Analyst at Forrester Research,examines the growing need to verify physical non-identity documents in digital onboarding. These documents include bank statements, telecom bills, utility bills, and receipts. Their verification is now as important as physical identity document verification, because organizations increasingly rely on both document types to onboard individuals and businesses. Regula was interviewed as one of the expert contributors. A significant portion of the analysis is based on mat
Loomis Sayles Proudly Celebrates 100 Years of Client Commitment and Investment Excellence6.1.2026 14:00:00 EET | Press release
Loomis, Sayles & Company, the investment manager with $425 billion in assets under managementi, proudly marks its centennial year, celebrating a legacy of independent thinking and a relentless commitment to helping clients achieve their goals. Founded in January 1926, Loomis Sayles has grown to serving over 1,000 institutional clients in 28 countries offering differentiated investment solutions across fixed income, equity and alternative markets. “Reaching a century is rare. Doing so with the continued trust of clients and partners around the world is exceptional and we are honored to celebrate with all of them,” said Kevin Charleston, Chairman and Chief Executive Officer of Loomis Sayles. “As Loomis Sayles celebrates its 100th anniversary, we look ahead with gratitude for the opportunity to continue growing and innovating alongside those we serve.” A Legacy of Client Commitment and High-Conviction Analysis Throughout its history, Loomis Sayles has remained steadfast in its mission: to
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP3606.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Radial is building a national network of clinics across the U.S., delivering interventional, evidence-based treatments for mental health conditions. The co-founders have a mission-driven background in designing customer-centric care and bui
Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries6.1.2026 12:30:00 EET | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi") today introduced HMAX by Hitachi at CES 2026. HMAX by Hitachi is a suite of next-generation solutions that brings the power of AI to social infrastructure. By harnessing vast data from physical and digital assets, integrating advanced AI, and applying Hitachi’s unmatched domain expertise, HMAX tackles the most complex social infrastructure challenges—maximizing outcomes and value for our clients and society. These solutions are derived from the formalized HMAX design principles, integrating a dynamic collection of advanced technologies and a robust partner ecosystem that helps elevate end-system reliability and performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106885363/en/ HMAX by Hitachi: the suite of next-generation solutions that brings the power of AI to social infrastructure. HMAX combines data collected from physical and digital assets such as sensors, industrial equipm
Pandorum Technologies and Nucelion Therapeutics Announce Strategic Collaboration to Manufacture Exosome-Based Tissue Regenerative Therapy for Ocular Diseases in APAC Markets6.1.2026 12:00:00 EET | Press release
Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad based Nucelion Therapeutics, a specialized contract research, development and manufacturing organization (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106214233/en/ This strategic collaboration aligns with a shared vision, as Pandorum’s asset(s) progress toward clinical trials. By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world. “Pandorum is building a gl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom